|Articles|April 16, 2007
Fixed-combination products offer option for greater IOP-lowering
Fixed-combination therapies may have a role in glaucoma management when monotherapy reduces IOP but not sufficiently to reach the target level, said Luca Rossetti, MD, professor of ophthalmology, University of Milan, Italy.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
2
First patient treated in ViaLase’s IDE trial
3
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5











































.png)


